Kinetics of development and characteristics of antibodies induced in cancer patients against yeast expressed rDNA derived granulocyte macrophage colony stimulating factor (GM-CSF)

Cytokine

Volumn 29, Issue 2, 2005, Pages 56-66

  Rini, B ^b   Wadhwa, M ^a   Bird, C ^a   Small, E ^b   Gaines Das, R ^a   Thorpe, R ^a  

^a NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antibodies; Binding; Immunogenicity; Monitoring; Neutralizing

Indexed keywords

AMINO ACID; CYTOKINE ANTIBODY; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTRO ANTIBODY; NEUTRALIZING ANTIBODY; PROSTATE SPECIFIC ANTIGEN; RIBOSOME DNA; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIBODY DETECTION; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ARTICLE; BIOASSAY; CANCER PATIENT; CELL LINE; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; ESCHERICHIA COLI; GENE EXPRESSION; HUMAN; KINETICS; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; SIDE EFFECT; SURFACE PLASMON RESONANCE; YEAST;

AGED; ANTIBODIES; CROSS REACTIONS; DNA, RIBOSOMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; RECOMBINANT PROTEINS; SACCHAROMYCES CEREVISIAE; TREATMENT OUTCOME;

EID: 10344235992     PISSN: 10434666     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cyto.2004.09.009     Document Type: Article

References (35)

1. S.J. Freedland, A.J. Pantuck, J. Weider, A. Zisman, and A.S. Belldegrun Immunotherapy of prostate cancer Curr Urol Rep 2 2001 242 247
2. H. Mellstedt, J. Fagerberg, J.E. Frodin, L. Henriksson, A.L. Hjelm-Skog, and M. Liljefors Augmentation of the immune response with granulocyte-macrophage colony-stimulating factor and other hematopoietic growth factors Curr Opin Hematol 6 1999 169 175
3. S. Markowicz, and E.G. Engleman Granulocyte-macrophage colony-stimulating factor promotes differentiation and survival of human peripheral blood dendritic cells in vitro J Clin Invest 85 1990 955 961
4. C.P. Larsen, S.C. Ritchie, R. Hendrix, P.S. Linsley, K.S. Hathcock, and R.J. Hodes Regulation of immunostimulatory function and costimulatory molecule (B7-1 and B7-2) expression on murine dendritic cells J Immunol 152 1994 5208 5219
5. P. Morrissey, L. Bressler, L. Park, A. Alpert, and S. Gillis Granulocyte-macrophage colony-stimulating factor augments the primary antibody response by enhancing the function of antigen presenting cells J Immunol 139 1987 1113 1119
6. M. Vadas, N. Nicola, and D. Metcalf Activation of antibody dependent cell mediated cytotoxicity of human neutrophils and eosinophils by separate colony stimulating factors J Immunol 130 1983 795 799
7. P. Masucci, P. Wersall, P. Ragnhammar, and H. Mellstedt Granulocyte monocyte colony stimulating factor augments the cytotoxic capacity of lymphocytes and monocytes in antibody-dependent cellular cytotoxicity Cancer Immunol. Immunother 29 1989 288 292
8. J.R. Gamble, M.J. Elliott, E. Jaipargas, A.F. Lopez, and M.A. Vadas Regulation of human monocyte adherence by granulocyte-macrophage colony-stimulating factor Proc Natl Acad Sci USA 86 1989 7169 7173
9. G. Dranoff, E. Jaffee, A. Lazenby, P. Golumbek, H. Levitsky, and K. Brose Vaccination with irradiated tumor cells engineered to secrete murine granulocyte macrophage colony-stimulating factor stimulates potent, specific and long-lasting anti-tumor immunity Proc Natl Acad Sci USA 90 1993 3539 3543
10. J. Vieweg, F.M. Rosenthal, R. Bannerji, W.D. Heston, W.R. Fair, and B. Gansbacher Immunotherapy of prostate cancer in the Dunning rat model: use of cytokine gene modified tumor vaccines Cancer Res 54 1994 1760 1765
11. E.J. Small, D.M. Reese, B. Um, S. Whisenant, S.C. Dixon, and W.D. Figg Therapy of advanced prostate cancer with granulocyte-macrophage colony-stimulating factor Clin Cancer Res 5 1999 1738 1744
12. B. Rini, V. Weinberg, R. Bak, and E.J. Small Prostate-specific antigen kinetics as a measure of the biologic effect of granulocyte-macrophage colony-stimulating factor in patients with serologic progression of prostate cancer J Clin Oncol 21 2003 99 105
13. P. Ragnhammar, H.J. Friesen, J.E. Frodin, A.K. Lefvert, M. Hassan, and A. Osterborg Induction of anti-recombinant human granulocyte-macrophage colony-stimulating factor (Escherichia coli-derived) antibodies and clinical effects in non-immunocompromised patients Blood 84 1994 4078 4087
14. J.G. Gribben, S. Devereux, N.S.B. Thomas, M. Keim, H.M. Jones, and A.H. Goldstone Development of antibodies to unprotected glycosylation sites on recombinant human GM-CSF Lancet 335 1990 434 437
15. J.A. Thompson, D.J. Lee, P. Kidd, E. Rubin, J. Kaufman, and E.M. Bonnem Subcutaneous granulocyte macrophage colony-stimulating factor in patients with myelodysplastic syndrome: toxicity pharmacokinetics and hematological effects J Clin Oncol 7 1989 629 637
16. M. Wadhwa, C. Bird, J. Fagerberg, R. Gaines-Das, P. Ragnhammar, and H. Mellstedt Production of neutralizing granulocyte-macrophage colony-stimulating factor (GM-CSF) antibodies in carcinoma patients following GM-CSF combination therapy Clin Exp Immunol 104 1996 351 358
17. M. Wadhwa, A.-L. Skog, C. Bird, P. Ragnhammar, M. Liljefors, and R. Gaines-Das Immunogenicity of granulocyte-macrophage colony-stimulating factor (GM-CSF) products in patients undergoing combination therapy with GM-CSF Clin Cancer Res 5 1999 1353 1356
18. G. Ullenhag, C. Bird, P. Ragnhammar, J.E. Frödin, K. Strigård, and A. Österborg Incidence of GM-CSF antibodies in cancer patients receiving GM-CSF for immunostimulation Clin Immunol 99 2001 65 74
19. J.M. Wood, R.E. Gaines-Das, J. Taylor, and P. Chakravorty Comparison of influenza serological techniques by international collaborative study Vaccine 12 1994 167 174
20. A. Meager, M. Wadhwa, C. Bird, P. Dilger, R. Thorpe, and J. Newsom-Davis Spontaneously occurring neutralizing antibodies against granulocyte- macrophage colony stimulating factor (GM-CSF) in patients with autoimmune disease Immunology 97 1999 526 532
21. R. Steis, and D. Longo Clinical relevance of recombinant interferon-alpha 2a antibodies in patients with hairy cell leukaemia J Interferon Res 14 1994 207 209
22. G. Antonelli, G. Giannelli, M. Pistello, F. Maggi, L. Vatteroni, and M. Currenti Clinical significance of recombinant interferon-alpha2a neutralizing antibodies in hepatitis patients J Interferon Res 14 1994 211 213
23. N. Casadevall, J. Nataf, B. Viron, A. Kolta, J.J. Kiladjian, and P. Martin-Dupont Pure red cell aplasia and anti- erythropoietin antibodies against human erythropoietin in patients treated with recombinant erythropoietin N Engl J Med 346 2002 469 475
24. O.A. Khan, and S.S. Dhib-Jalbut Neutralizing antibodies to interferon beta-1a and interferon beta-1b in MS patients are cross-reactive Neurology 51 1988 1698 1702
25. O. Prummer Treatment-induced antibodies to interleukin-2 Biotherapy 10 1997 15 24
26. J.G. Scharenberg, A.G. Stam, B.M. von Blomberg, G.J. Roest, P.A. Palmer, and C.R. Franks The development of anti-interleukin-2 (IL-2) antibodies in cancer patients treated with recombinant IL-2 Eur J Cancer 12 1994 1804 1809
27. G. Antonelli, and F. Dianzani Development of antibodies to interferon beta in patients: technical and biological aspects Eur Cytokine Netw 10 1999 413 422
28. G. Antonelli, E. Simeoni, F. Bagnato, C. Pozzilli, O. Turriziani, and R. Tesoro Further study on the specificity and incidence of neutralizing antibodies to interferon (IFN) in relapsing remitting multiple sclerosis patients treated with IFN beta-1a or IFN beta-1b J Neurol Sci 168 1999 131 136
29. S.J. Swanson, S.J. Jacobs, D. Mytych, C. Shah, S.R. Indelicato, and R.W. Bordens Applications for the new electrochemiluminescent (ECL) and biosensor technologies Dev Biol Stand 97 1999 135 147
30. S.J. Swanson, D. Mytych, and J. Ferbas Use of biosensors to monitor the immune response Dev Biol 109 2002 71 78
31. M. Wadhwa, C. Bird, P. Dilger, R. Gaines-Das, and R. Thorpe Strategies for the detection, measurement and characterization of unwanted antibodies induced by therapeutic biologicals J Immunol Methods 278 2003 1 17
32. D. McNeel, K. Schiffman, and M. Disis Immunization with recombinant human granulocyte-macrophage colony-stimulating factor as a vaccine adjuvant elicits both a cellular and humoral response to recombinant human granulocyte-macrophage colony-stimulating factor Blood 93 1999 2653 2659
33. A.W. Burgess, C.G. Begley, G.R. Johnson, A.F. Lopez, D.J. Williamson, and J.J. Mermod Purification and properties of bacterially synthesized human granulocyte-macrophage colony stimulating factor Blood 69 1987 43 51
34. T. Kitamura, T. Tange, T. Terasawa, S. Chiba, T. Kuwaki, and K. Miyagawa Establishment and characterization of a unique human cell line that proliferates dependently on GM-CSF, IL-3, or erythropoietin J Cell Physiol 140 1989 323 334
35. T.B.L. Kirkwood Geometric means and measures of dispersion Biometrics 35 1979 908 909